• darkblurbg

    Developing therapies

    for type 1 diabetes

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

Clinical Project Assistants with knowledge of clinical research in Life Science

We welcome candidates with relevant life science experience to join our team.

Calendar

 Dates for financial information and other events
Data pager
Data pager
12
April 13 − April 14, 2021
Drug Discovery & Development with AI & ML
3rd Annual Forum - Online Conference
April 20 − April 23, 2021
NLS Days
Nordic Life Science Days 2021 digital conference
June 2 − June 5, 2021
ATTD 2021
Advanced Technologies & Treatments for Diabetes virtual conference
June 23, 2021
Quarterly Report III
Quarterly Report 3 2020/2021

Company Presentation

 February 8, 2021

The Phase 3 trial is based on the notion of precision medicine, where only individuals that we know beforehand to have a high likelihood of benefitting from the treatment will be enrolled.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 2, 20/21

THE COMPANY

Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)


Read More

Order GAD for preclinical research

GAD PRODUCTS